News Sentiment

CMPS sentiment intelligence

Compass Pathways Plc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 63 Constructive news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Care Facilities Read-through group
Latest close 13.64 Week of 10 Jul 2026
Weighted tone 63/100

Constructive news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 55

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

+0.1% over one week, +12.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Should COMP360’s Durable Phase 3 Results and FDA Momentum Require Action From COMPASS Pathways (CMPS) Investors?

Market Reaction

Balanced read

64/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction 0.1% Price digesting
Trend fit Trend active 12.9% over four weeks
Fair value 102.7% Materially above fair value
Sentiment confirms active trend Positive but stretched

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 28
Neutral 27
Negative 0

Relevance

Why the article matched

Direct first
Direct company coverage 55
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 8
simplywall.st 7
Market source 7
TradingView 6
Investing.com 5
Seeking Alpha 3
TradingKey 3
Stocktwits 2

Event Lens

What the news is about

Classified themes
Market update 35
Earnings 12
Analyst action 5
Macro sensitivity 1
Capital return 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
Market source Direct company coverage

Is COMPASS Pathways plc (CMPS) Stock a Psychedelic Medicine Opportunity After Positive COMP360 Data?

COMPASS Pathways plc (CMPS) is being considered a strong psychedelic medicine opportunity after positive 26-week results from its Phase 3 COMP006 study for COMP360, a treatment for resistant depression. Oppenheimer reaffirmed its Outperform rating and $20 price target, highlighti

Tone
Positive 74/100
Event
Analyst action
Published
15 Jul 2026 09:22
Source
Market source
Seeking Alpha Direct company coverage

Compass Pathways stock upgraded at Evercore ISI (CMPS:NASDAQ)

Evercore ISI has upgraded Compass Pathways (CMPS) to Outperform from Inline and significantly increased its price target to $21 from $8. This upgrade follows the release of updated late-stage trial results showcasing the long-term efficacy of the U.K.-based biotech's psychedelic

Tone
Positive 70/100
Event
Analyst action
Published
08 Jul 2026 16:40
Source
Seeking Alpha
TradingView Direct company coverage

Price to book forward of COMPASS Pathways Plc - American Depository Shares – NASDAQ:CMPS

This page from TradingView displays the "Price to book forward" metric for COMPASS Pathways Plc - American Depository Shares (NASDAQ: CMPS). It indicates the stock's financial overview, specifically its price-to-book ratio on a forward-looking basis. The content provides basic co

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 03:06
Source
TradingView
www.marketscreener.com Direct company coverage

Compass Pathways Reports Six-Month Data from Second Phase 3 Trial of Comp360 for Treatment-Resistant Depression

Compass Pathways announced positive 26-week data from its second Phase 3 COMP006 trial for COMP360 psilocybin in treatment-resistant depression (TRD), confirming its rapid onset and durable profile. The findings, building on previous trial results, showed that 39% of patients in

Tone
Positive 73/100
Event
Earnings
Published
08 Jul 2026 01:40
Source
www.marketscreener.com
Clinical Trials Arena Direct company coverage

Compass’ psilocybin shows six-month durability in Phase III trial

Compass Pathways' psilocybin-based therapy, COMP360, has demonstrated six-month durability in a Phase III trial for treatment-resistant depression (TRD), building on earlier six-week data. The therapy showed rapid onset and sustained response, with a generally well-tolerated safe

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 01:39
Source
Clinical Trials Arena
Investor's Business Daily Direct company coverage

Why This Psychedelics Stock Reversed Its Bearish Fortunes

Compass Pathways (CMPS) stock saw a significant turnaround after announcing positive clinical trial results for its psilocybin-based treatment for depression. The treatment showed clinically meaningful improvements in 39% of patients after two fixed doses, with durable results la

Tone
Positive 74/100
Event
Earnings
Published
07 Jul 2026 20:12
Source
Investor's Business Daily
AllSci Direct company coverage

COMP360 Psilocybin Shows Durable TRD Benefit

Compass Pathways has announced 26-week data from its second Phase III trial of COMP360, a synthetic psilocybin formulation for treatment-resistant depression (TRD). The results indicate that antidepressant effects observed at six weeks were maintained through six months, strength

Tone
Positive 71/100
Event
Earnings
Published
07 Jul 2026 18:11
Source
AllSci
Investing News Network Direct company coverage

Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile

Compass Pathways has announced positive six-month data from its second Phase 3 trial (COMP006) for COMP360, a psilocybin treatment for treatment-resistant depression (TRD). The results reinforce the rapid onset and durable effectiveness of COMP360, showing sustained benefit up to

Tone
Positive 71/100
Event
Earnings
Published
07 Jul 2026 13:12
Source
Investing News Network
Intellectia AI Direct company coverage

Compass Pathways Releases New Data on COMP360 for Treatment-Resistant Depression

Compass Pathways has released new data from its Phase 3 COMP006 trial for COMP360, a treatment for resistant depression, showing rapid onset and durable clinical effects. The therapy also maintains a strong safety profile and is on track for a rolling FDA new drug application sub

Tone
Positive 72/100
Event
Market update
Published
07 Jul 2026 12:20
Source
Intellectia AI
Seeking Alpha Direct company coverage

Compass gains on new late-stage trial data for psychedelic therapy in depression

Compass Pathways (CMPS) saw an ~8% rise in early premarket trading after releasing new 26-week data from Part B of an ongoing late-stage trial for its psychedelic therapy, COMP360. The trial is evaluating COMP360 as a treatment for resistant depression. This positive data follows

Tone
Positive 75/100
Event
Market update
Published
07 Jul 2026 11:42
Source
Seeking Alpha
Stock Titan Direct company coverage

Compass Pathways says second psilocybin trial kept depression benefit for 6 months

Compass Pathways announced 26-week results from its second Phase 3 trial (COMP006) for COMP360, a synthetic psilocybin formulation for treatment-resistant depression (TRD), confirming rapid onset and durable benefit for at least six months. This data, consistent with previous tri

Tone
Positive 91/100
Event
Earnings
Published
07 Jul 2026 10:42
Source
Stock Titan
Stock Titan Direct company coverage

Phase 3 TRD results move Compass (NASDAQ: CMPS) toward COMP360 NDA

Compass Pathways has reported positive 26-week data from its Phase 3 COMP006 trial for COMP360 psilocybin treatment in treatment-resistant depression (TRD), showing durable efficacy and a well-tolerated safety profile. The company is proceeding with a rolling NDA submission to th

Tone
Positive 82/100
Event
Earnings
Published
07 Jul 2026 10:42
Source
Stock Titan
Investing.com Direct company coverage

Compass Pathways reports 6-month data from phase 3 TRD trial

Compass Pathways announced that its COMP006 Phase 3 trial for COMP360 psilocybin in treatment-resistant depression (TRD) showed durable benefits over 26 weeks, with 39% of participants achieving significant reduction in depression scores. The company plans a rolling New Drug Appl

Tone
Positive 74/100
Event
Market update
Published
07 Jul 2026 10:42
Source
Investing.com
TradingView Direct company coverage

Compass Pathways: COMP360 shows rapid onset, durable 26-week benefit in Phase 3 COMP006; rolling NDA on track for Q4

Compass Pathways reported positive 26-week results for its COMP360 treatment in treatment-resistant depression from the Phase 3 COMP006 trial, showing rapid onset and durable clinical benefits. A rolling NDA submission is progressing as planned for completion in Q4 2026. The comp

Tone
Positive 70/100
Event
Earnings
Published
07 Jul 2026 10:42
Source
TradingView
Investing.com South Africa Direct company coverage

Why is Compass Pathways stock gaining today? By Investing.com

Compass Pathways Plc (CMPS) stock gained 3.5% in pre-market trading, continuing its recovery from a 52-week low. This surge is driven by anticipation for the company's COMP006 Phase 3 trial durability data, expected in early Q3 2026, and a planned New Drug Application submission

Tone
Positive 72/100
Event
Market update
Published
06 Jul 2026 16:40
Source
Investing.com South Africa
TradingView Direct company coverage

Price to sales forward of COMPASS Pathways Plc - American Depository Shares – NASDAQ:CMPS

This article provides price to sales forward data for COMPASS Pathways Plc (NASDAQ: CMPS). It includes the period, value, change, and percentage change. The content highlights financial data sourced from ICE Data Services and FactSet for the company.

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 23:12
Source
TradingView
Business Wire Direct company coverage

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Compass Pathways plc announced equity awards granted to eight new non-executive employees under its 2026 Inducement Plan. These grants, consisting of options and restricted share units, were made on July 1, 2026, as a material inducement for employment and are in compliance with

Tone
Positive 61/100
Event
Market update
Published
02 Jul 2026 10:30
Source
Business Wire
The National Law Review Direct company coverage

Compass Pathways Announces FDA Granted NDA Rolling Review Request

Compass Pathways announced that the FDA granted its NDA rolling review request for COMP360, their proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD). The company also received a Commissioner's National Priority Voucher (CNPV), which provides

Tone
Positive 92/100
Event
Market update
Published
01 Jul 2026 23:11
Source
The National Law Review
TradingView Direct company coverage

Enterprise value to EBIT forward of COMPASS Pathways Plc - American Depository Shares – NASDAQ:CMPS

The article focuses on the enterprise value to EBIT forward metric for COMPASS Pathways Plc (NASDAQ: CMPS). It appears to be a financial data page from TradingView, providing an overview of the company's financial information within the health technology and biotechnology sectors

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 05:09
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of COMPASS Pathways Plc - American Depository Shares – NASDAQ:CMPS

This article provides financial information for COMPASS Pathways Plc (CMPS) listed on the NASDAQ Stock Market, specifically focusing on its price-to-earnings forward ratio. The content appears to be a stub or an empty data table from TradingView, indicating that specific financia

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 12:41
Source
TradingView
Investing.com Direct company coverage

Compass Pathways stock hits 52-week high at 14.77 USD

Compass Pathways Plc (CMPS) has hit a new 52-week high of $14.76, reflecting a robust 411% one-year stock performance and a market capitalization of $1.98 billion. This surge is attributed to investor confidence in the psychedelic therapy sector, recent positive Phase 3 data for

Tone
Positive 73/100
Event
Market update
Published
26 Jun 2026 16:10
Source
Investing.com